Keyphrases
Phase II Trial
100%
Metastatic Melanoma
100%
Interleukin-2
100%
Stable Disease
100%
Dendritic Cell Vaccine
100%
Metronomic Cyclophosphamide
100%
HLA-A2
75%
Immune Response
50%
Celecoxib
50%
Cyclophosphamide
50%
Number of Patients
25%
Clinical Efficacy
25%
Progressive Disease
25%
Prognostic Factors
25%
Derived Peptide
25%
Vaccination
25%
Dendritic Cells
25%
Antigen-presenting Cells
25%
Regulatory T Cells
25%
Human Telomerase Reverse Transcriptase (hTERT)
25%
Survivin
25%
Peptide-HLA
25%
Tumor Lysate
25%
Immunosuppressive Mechanisms
25%
Specific Immune Response
25%
COX-2 Inhibitors
25%
ELISpot Assay
25%
Antigen-specific Immune Response
25%
Immune Inhibition
25%
Medicine and Dentistry
Metastatic Melanoma
100%
Interleukin 2
100%
Phase II Trials
100%
Cyclophosphamide
100%
Dendritic Cell
100%
Disease
80%
Immune Response
80%
Celecoxib
40%
Neoplasm
20%
Antigen Specificity
20%
Progressive Disease
20%
Prognostic Factor
20%
Protein P53
20%
Antigen Presenting Cell
20%
Regulatory T Cell
20%
Immunosuppressive Drug
20%
Survivin
20%
Dendritic Cell Vaccine
20%
Enzyme Linked Immunospot Assay
20%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Vaccination Policy
100%
Phase II Trials
100%
Interleukin 2
100%
Cyclophosphamide
100%
Metastatic Melanoma
100%
Celecoxib
40%
Neoplasm
20%
Immunosuppressive Agent
20%
Protein P53
20%
Dendritic Cell Vaccine
20%
Survivin
20%
Enzyme-Linked Immunospot Assay
20%
Immunology and Microbiology
Vaccination Policy
100%
Dendritic Cell
100%
Interleukin 2
100%
Cyclophosphamide
100%
Immune Response
80%
Antigen Presenting Cell
20%
Antigen Specificity
20%
Regulatory T Cell
20%
P53
20%
Immunosuppressive Drug
20%
Cell Lysate
20%
Enzyme-Linked Immunospot Assay
20%
Dendritic Cell Vaccine
20%